Лікування хворих на дифузну В-великоклітинну лімфому групи високого ризику: стан проблеми

K. S. Filonenko; I. A. Kriachok; A. V. Martynchyk

doi:10.31640/LS-2017(1-2)02

K. S. Filonenko National Cancer Institute
I. A. Kriachok National Cancer Institute
A. V. Martynchyk National Cancer Institute

DOI: https://doi.org/10.31640/LS-2017(1-2)02

Keywords: diffuse large B-cell lymphoma, high-risk group, risk factors, therapy, rituximab, survival

Abstract

Diffuse large B-cell lymphoma (DLBCL) is potentially curative disease. Nevertheless this group of patients is very heterogeneous. There are several scales for the assessment of the disease risk. According to the International Prognostic index 5-year overall survival of patients from high-risk group is 26 % comparing to 73 % in patients from low-risk group. There is no standard approach to the treatment of patients with DLBCL from high-risk group. The literature review of the efficacy of different treatment regimens in patients with DLBCL from high-risk group is presented in the article.

Downloads

Download data is not yet available.

References

Федоренко З. П., Гайсенко А. В., Гулак Л. О. та ін. Рак в Україні, 2008–2009. Захворюваність, смертність, показники діяльності онкологічної служби // Бюл. Нац. канцер-реєстру України. – 2010. – № 11. – 111 с.

Федоренко З. П., Михайлович Ю. Й., Гулак Л. О. та ін. Рак в Україні, 2010–2011. Захворюваність, смертність, показники діяльності онкологічної служби // Там само. – 2013. – № 14. – 120 с.

A Predictive Model for Aggressive Non-Hodgkin's Lymphoma The International Non-Hodgkin's Lymphoma Prognostic Factors Project // N. Engl. J. Med. – 1993. – Vol. 329. – Р. 987–994.

Amen F., Horncastle D., Elderfield K. et al. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients // Histopathology. – 2007. – Vol. 51, N 1. – Р. 70–79.

Bing Cao, Xiaoyan Zhou, Dongmei J. I. et al. Central nervous system involvement in adult patients with diffuse large B-cell lymphoma: Influence of rituximab // Oncol. Lett. – 2012. – Vol. 4, N 3. – Р. 541–545.

Cunningham D., Hawkes E. A., Jack A. et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles // Lancet. – 2013. – Vol. 381, N 9880. – Р. 1817–1826.

Cunningham D., Smith P., Mouncey P. et al. R-CHOP14 versus R-CHOP21: Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma // J. Clin. Oncol. – 2011. – Vol. 29, N 15 (Suppl.). – Аbstr. 8000.

Fitoussi O., Belhadj K., Mounier N. et al. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA // Haematologica. – 2011. – Vol. 96, N 8. – Р. 1136–1143.

Gang A. O., Strøm C. , Pedersen M. et al. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group Ann. // Ann. Oncol. – 2012. – Vol. 23, N 1. – Р. 147–153.

Glass B., Kloess M., Bentz M. et al. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma // Blood. – 2006. – Vol. 107, N 8. – Р. 3058–3064.

Huang B. T., Zeng Q. C., Yu J. et al. How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience / // J. Cancer. Res. Clin. Oncol. – 2012. – Vol. 138, N 1. – Р. 125–132.

Jurczak W., Ochrem B., Giza A. et al. Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group // Pol. Arch. Med. Wewn. – 2015. – Vol. 125, N 10. – Р. 741–748.

Milpied N.-J. , Legouill S., Lamy T. et al. No benefit of first-line rituximab (R)-high-dose therapy (R-HDT) over R-CHOP14 for young adults with diffuse large b-cell lymphoma. Preliminary results of the GOELAMS 075 Prospective Multicentre Randomized Trial // J. Clin. Oncol. – 2010. – Vol. 116. – Р. 685.

Morgan G., Vornanen M., Puitinen J. et al. Changing trends in the incidence of non-Hodgkin's lymphoma in Europe. Biomed Study Group // Ann. Oncol. – 1997. – Vol. 8 (Suppl. 2). – Р. 49–54.

Pfreundschuh M., Trumper L., Osterborg A. et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group // Lancet Oncol. – 2006. – Vol. 7. – Р. 379–391.

Récher C., Coiffier B., Haioun C. et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial // Lancet. – 2011. – Vol. 378, N 9806. – Р. 1858–1867.

Savage K. J. , Johnson N. A., Ben-Neriah S. et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy // Blood. – 2009. – Vol. 114, N 17. – Р. 3533–3537.

Schmitz N., Nickelsen M., Ziepert M. et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1) // Lancet Oncol. – 2012. – Vol. 13, N 12. – Р. 1250–1259.

Sehn L. H., Berry B., Chhanabhai M. et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP // Blood. – 2007. – Vol. 109, N 5. – Р. 1857–1861.

Stiff P. J., Unger J. M., Cook J. et al. Randomized phase III U.S. / Canadian intergroup trial (SWOG S9704) comparing CHOP {+/-} R for eight cycles to CHOP {+/-} R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL) // J. Clin. Oncol. – 2011. – Vol. 29 (Suppl. 15). – Р. 8001.

Swerdlow S. H., Campo E., Harris N. L. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. – 4 ed. – WHO, 2008. – 439 р.

Tai W. M., Chung J., Tang P. L. et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab // Ann. Hematol. – 2011. – Vol. 90, N 7. – Р. 809–818.

Tarella C. , Zanni M., Di Nicola M. et al. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) // Leukemia. – 2007. – Vol. 21. – Р. 1802–1811.

Tilly H., Gomes M. da Silva, Vitolo U. et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. – 2015. – Vol. 26 (Suppl. 5). – Р. 116–125.

Vaidya R., Witzig T. E. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era // Ann. Oncol. – 2014. – Vol. 25, N 11. – Р. 2124–2133.

Vitolo U., Chiappella A., Brusamolino E. et al. A randomized multicentre phase III study for first line treatment of young patients with high risk (AAIPI 2–3) diffuse large B-cell lymphoma (DLBCL): rituximab (R) plus dose-dense chemotherapy CHOP14/MEGACHOP14 with or without intnesified high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Results of DLCL04 trial of Italian Lymphoma Foundation (FIL) // Ann. Oncol. – 2011. – Vol. 22. – Р. 106.

Vitolo U., Ziepert M., Glass B. et al. Comparison Of R-CHOP14 and R-CHOEP14 As First Line Treatment In Young Patients With High-Risk (aaIPI 2-3) Diffuse Large B-Cell Lymphoma (DLBCL): A Joint Analysis Of Two Prospective Phase III Randomized Trials Conducted By The Fondazione Italiana Linfomi (FIL) and The German High-Grade Lymphoma Study Group (DSHNHL) // Blood. – 2013. – Vol. 122, N 21. – Р. 4341.

Vitolo U., Chiappella A., Angelucci E. et al. Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study // Haematologica. – 2009. – Vol. 94. – Р. 1250–1258.

Wang Yucai, Shen Yan, Yang Fang et al. Rituximab maintenance Therapy in B-cell lymphoma: A meta-analysis // J. Clin. Oncol. – 2015. – Vol. 33 (Suppl.). – Аbstr 8551.

Wilson W. H., Bryant G., Bates S. et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma // J. Clin. Oncol. – 1993. – Vol. 11, N 8. – Р. 1573–1582.

Wilson W. H., Grossbard M. L. , Pittaluga S. et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy // Blood. – 2002. – Vol. 99, N 8. – Р. 2685–2693.

Treatment of patients with diffuse large B-cell lymphoma from high-risk group

Abstract

Downloads

References